Scarica l'app Stockscreener
5.85
2.81%
0.16
Dopo l'orario di chiusura:
6.00
0.15
+2.56%
Precedente Chiudi:
$5.69
Aprire:
$6
Volume 24 ore:
49,487
Relative Volume:
0.44
Capitalizzazione di mercato:
$77.74M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-4.88%
1M Prestazione:
-26.04%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.69
$6.00
Intervallo di 1 settimana:
$5.58
$6.36
Portata 52W:
$4.575
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Nome
Onkure Therapeutics Inc
Settore
Industria
Telefono
(720) 307-2892
Indirizzo
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Confronta OKUR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
5.85 | 77.74M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-05 | Iniziato | Leerink Partners | Outperform |
| 2024-10-10 | Iniziato | Oppenheimer | Outperform |
| 2023-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-12-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Iniziato | William Blair | Outperform |
| 2023-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2023-07-03 | Iniziato | BofA Securities | Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-27 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-22 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-05-04 | Iniziato | Jefferies | Buy |
| 2021-05-04 | Iniziato | Piper Sandler | Overweight |
| 2021-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Onkure Therapeutics Inc Borsa (OKUR) Ultime notizie
Vanguard Group Inc's Strategic Acquisition of OnKure Therapeutics Shares - GuruFocus.com
After A Clear Safety Picture, OnKure Prepares For Pivotal PIKture-01 Data On OKI-219 - RTTNews
Jones Trading sets OnKure stock Buy rating, $32 target - MSN
Jones Trading sets OnKure stock Buy rating, $32 target By Investing.com - Investing.com South Africa
Jones Trading Initiates Coverage of OnKure Therapeutics (OKUR) with Buy Recommendation - MSN
OnKure Therapeutics (NASDAQ:OKUR) Trading Down 3.4% – Here’s Why - Defense World
Reneo Pharmaceuticals stock hits 52-week low at $5.66 By Investing.com - Investing.com Australia
Reneo Pharmaceuticals stock hits 52-week low at $5.66 - Investing.com India
Reneo Pharmaceuticals stock hits 52-week low at $7.64 By Investing.com - Investing.com Australia
Reneo Pharmaceuticals stock hits 52-week low at $7.64 - Investing.com India
OnKure Therapeutics (NASDAQ:OKUR) Trading 4% Higher – Time to Buy? - Defense World
Reneo Pharmaceuticals stock hits 52-week low at $7.91 By Investing.com - Investing.com Nigeria
Reneo Pharmaceuticals stock hits 52-week low at $7.91 - Investing.com India
OKUR Stock Hits 52-Week Low at $10.51 Amid Market Challenges - Investing.com Australia
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 - Markets Insider
OnKure reports positive early trial data for cancer drug OKI-219 - Investing.com India
OnKure Therapeutics Advances Cancer Drug Trials - TipRanks
Form 424B3 OnKure Therapeutics, - StreetInsider.com
SEC Form 424B3 filed by OnKure Therapeutics Inc. - Quantisnow
OnKure Therapeutics announces safety, pharmacokinetic data on OKI-219 - TipRanks
OnKure's OKI-219 Cancer Drug Shows Promising Safety Data, 95% Tumor Marker Reduction in Clinical Trial - StockTitan
Brokers Offer Predictions for OKUR FY2024 Earnings - Defense World
Leerink Partners Initiates Coverage of OnKure Therapeutics (OKUR) with Outperform Recommendation - MSN
OnKure Therapeutics stock has strong potential with Outperform rating from Leerink - Investing.com
OnKure Therapeutics Reports Strategic Merger and Financial Updates - TipRanks
OnKure Announces New Date for Upcoming Investor Call - GlobeNewswire
Head to Head Survey: OnKure Therapeutics (OKUR) vs. Its Rivals - Defense World
OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth - MSN
OnKure Therapeutics (OKUR) vs. The Competition Head-To-Head Analysis - Defense World
OnKure Therapeutics' (OKUR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
OnKure Therapeutics announces accounting firm change - Investing.com India
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
OnKure to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium - GlobeNewswire
vTv Therapeutics Faces License Agreement Termination - Yahoo Finance
VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch
vTv Therapeutics ends key license agreement with OnKure - Investing.com
vTv Therapeutics ends key license agreement with OnKure By Investing.com - Investing.com UK
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond (OKUR) - Seeking Alpha
Q3 Earnings Forecast for OKUR Issued By HC Wainwright - MarketBeat
Onkure Therapeutics Inc Azioni (OKUR) Dati Finanziari
Non sono disponibili dati finanziari per Onkure Therapeutics Inc (OKUR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Onkure Therapeutics Inc Azioni (OKUR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Sep 24 '24 |
Buy |
1.41 |
29,600 |
41,866 |
3,388,649 |
| Leonard Braden Michael | 10% Owner |
Sep 17 '24 |
Buy |
1.36 |
55,300 |
75,108 |
3,358,243 |
| Leonard Braden Michael | 10% Owner |
Sep 18 '24 |
Buy |
1.40 |
806 |
1,128 |
3,359,049 |
| Leonard Braden Michael | 10% Owner |
Sep 16 '24 |
Buy |
1.37 |
172,747 |
236,871 |
3,302,943 |
| Leonard Braden Michael | 10% Owner |
Sep 13 '24 |
Buy |
1.31 |
150,000 |
196,950 |
3,130,196 |
| Leonard Braden Michael | 10% Owner |
Sep 12 '24 |
Buy |
1.40 |
36,176 |
50,523 |
2,980,196 |
| Leonard Braden Michael | 10% Owner |
Aug 13 '24 |
Buy |
1.39 |
171,339 |
238,590 |
2,843,533 |
| Leonard Braden Michael | 10% Owner |
Aug 14 '24 |
Buy |
1.41 |
100,487 |
142,008 |
2,944,020 |
| Leonard Braden Michael | 10% Owner |
May 14 '24 |
Buy |
1.54 |
414,281 |
639,578 |
2,672,194 |
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):